This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


trusted source


Cancer stem cells trigger macrophage aging in mouse study

Cancer stem cells trigger macrophage aging
(Top) Cancer stem cells produce interleukin-6 (IL-6), which induces senescence in macrophages (Mφ). In turn, these produce arginase-1 and inactivate T cells. As a result, cancer cells are not killed by immune system cells, leading to tumor formation. (Bottom) Non-cancer stem cells do not produce IL-6. Macrophages do not age and T cells are activated. Activated T cells destroy cancer cells, preventing tumor formation. Credit: Haruka Wada

Cancer stem cells cause the aging of macrophages in mice with healthy immune systems, creating conditions for the formation of tumors.

Cancerous tumors consist of a mixture of cells, the most important of which are . These cells are capable of establishing new by evading the . Research has focused on identifying biomarkers for cancer stem cells and developing therapies that target these cells. Unfortunately, candidate drugs developed from these efforts have so far not been very effective in clinical trials.

A research team led by Associate Professor Haruka Wada at Hokkaido University's Institute for Genetic Medicine has examined the mechanisms by which cancer stem cells evade immune response in mice models. They showed that cancer stem cells induce senescence in macrophages—the that are responsible for the first step of the destruction of cancer cells. Their findings were published in the Journal for ImmunoTherapy of Cancer.

Cancer stem cells trigger macrophage aging
Cancer stem cells (8B, top row) and noncancer stem cells (9G, bottom row) are associated with similar numbers of macrophages (F4/80); however, a much greater proportion of macrophages associated with cancer stem cells are senescent (CD38). Credit: Haruka Wada, et al. Journal for ImmunoTherapy of Cancer. November 8, 2023

"One of the biggest questions in the development of cancer is how cancer develops in individuals with a healthy immune system," explains Wada. "The majority of studies on cancer stem cells have been carried out in vitro or in immunodeficient mice models, which do not account for a fully functioning immune response. The lack of effectiveness of cancer stem cell-targeting drugs indicates that the immune response or lack thereof is more important than previously considered."

The team used two cell lines of glioblastoma tumor, one of which was capable of inducing tumor formation (cancer stem cell) and the other of which was not. In mice models, the cancer stem cells suppressed the proliferation of macrophages; further investigation showed that macrophages cultured with cancer stem cells exhibit senescence or cellular aging.

Macrophages were not the only immune cells affected; while the proliferation of T cells was unchanged, their antitumor activity was suppressed due to the immunosuppressive factors produced by senescent macrophages. The team identified interleukin 6 (IL-6) produced by cancer stem cells as the molecule responsible for triggering these effects.

  • Cancer stem cells trigger macrophage aging
    A C57BL/6 mouse used in the study. Credit: Haruka Wada
  • Cancer stem cells trigger macrophage aging
    When cancer stem cells modified to be unable to express interleukin-6 (8B-IL-6-KO) were transplanted into immunocompetent mice (C57BL/6), survival times of the mice increased significantly compared to mice that were transplanted with cancer stem cells that express IL-6 (8B-mock). Credit: Haruka Wada, et al. Journal for ImmunoTherapy of Cancer. November 8, 2023

The team also demonstrated that supplementing the mice inoculated with cancer stem cells with a molecule called nicotinamide mononucleotide resulted in the proliferation of non-senescent macrophages and reduced the immunosuppressive factors produced by senescent macrophages, preventing and leading to increased survival times in .

"Our results indicate that drugs targeting senescent could be a treatment for cancer—an unprecedented development," concluded Wada. "We believe that these drugs could be part of a treatment that prevents the new onset of tumors, as well as a therapy that prevents recurrence after ." Future work will focus on two avenues: confirming that this discovery holds true for cancers other than glioblastomas, and confirming that the findings apply to cancers in humans.

More information: Tumor cell-induced macrophage senescence plays a pivotal role in tumor initiation followed by stable growth in immunocompetent condition, Journal for ImmunoTherapy of Cancer (2023). DOI: 10.1136/jitc-2023-006677

Citation: Cancer stem cells trigger macrophage aging in mouse study (2023, November 14) retrieved 25 February 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Study finds carcinogen exposure makes cancer cells more susceptible to immune attack


Feedback to editors